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Developing primary palliative care
Completion of community palliative care
management form should be mandatory
Editor—Murray et al propose that people
with terminal conditions should be able to
die at home with dignity.1 They fall short of
initiating a practical, pragmatic, less idealis-
tic, cost neutral solution.
Once a patient has been identified as
requiring palliative care by their criterion
“Would I be surprised if my patient were to
die in the next 12 months?” a simple proce-
dure should compulsorily take place. A form
detailing palliative care management should
be completed by the patient’s general practi-
tioner. This form should include details of
the diagnosis, prognosis, and management
plans and be emailed or faxed to the out of
hours provider—the “unscheduled care
services” to which the editorial refers.
Additionally, any scheduled drugs that may
be required to keep the patient at home
should be prescribed and delivered to the
patient’s home. If these two simple proce-
dures became part of a national plan, many
(not all) of the problems that arise in the
community would be overcome.
The gold standards framework and
development of education and research
programmes are commendable. These
require adequate time and resources, as well
as the willingness of healthcare profession-
als to participate. In a health system with
limited resources, improving efficiency and
using existing resources is where this
programme should begin.
In hospital medicine completion of a
“do not resuscitate” form is mandatory.
Completion of an equivalent form for
palliative care management in the commu-
nity should be compulsory too. Only with a
compulsory procedure where accountability
and responsibility can be identified will
terminally ill patients be able to access
appropriate palliative care.
Julia Riley consultant in palliative medicine
Royal Marsden Hospital, London SW3 6JJ
Julia.Riley@rmh.nhs.uk
Competing interests: None declared.
1 Murray SA, Boyd K, Sheikh A, Thomas K, Higginson IJ.
Developing primary palliative care. BMJ 2004;329:1056-7.
(6 November.)
Changed role of general practitioners has
been taken into account
Editor—To say that general practitioners
should be in the front line to provide pallia-
tive care, as Murray et al say in their
editorial,1 is to misunderstand totally the
changed role of general practice in primary
care. From today most general practitioners
in the United Kingdom will have given up
their commitment out of hours, and the
health boards must have made alternative
on call arrangements.
General practice is responsible for 25%
of the week’s on-call; the other 75% is being
covered by the new out of hours organisa-
tions. Between 6 00 pm on a Friday and 8 00
am on a Monday there are 62 hours of out
of hours cover. A lot can happen in 62
hours.
A patient’s general practitioner can be
involved in setting up a care plan and can
pass that information on to the out of hours
service, but it is no longer possible for most
general practitioners to be involved person-
ally, or as a practice, in the out of hours pro-
vision of that care.
I have seen how complex some palliative
care can become. At times, front rooms
resemble intensive treatment units, with the
amount of equipment and pharmacology
that patients need to be kept comfortable in
their own home. One really has to question
the sense of bringing the hospice into the
house.
If more patients are to be given the right
to die with dignity at home then resources
will have to be increased. Specialist palliative
care nurses should be given more
autonomy, with an increase in their prescrib-
ing powers so as to avoid the current
nonsense where out of hours doctors must
drive to a patient’s house just to sign forms
such as the authorisation for an increase in
syringe driver rates.
Colin I Guthrie general practitioner
1448 Dumbarton Road, Glasgow G14 9DW
Grey_triken@hotmail.com
Competing interests: None declared.
1 Murray SA, Boyd K, Sheikh A, Thomas K, Higginson IJ.
Developing primary palliative care. BMJ 2004;329:1056-7.
(6 November.)
Community palliative care services are
not sufficiently funded
Editor—Murray et al say that community
palliative care should be available to more
patients, including those with non-
malignant disease.1 We report the reality of
achieving community care for patients
discharged from a cancer centre.
Data from 2000 consecutive patients
referred to a hospital palliative care team
were collected prospectively. Outcome was
categorised as discharge home (patient’s or
carer’s); transfer to another hospital or nurs-
ing home, transfer to specialist palliative
care unit, died in Ninewells, or referral back
to original medical or surgical team.
Performance status, using the palliative per-
formance scale (see bmj.com for details), was
determined at referral.2
Altogether 96% had cancer and 4%
non-malignant disease. On average, patients
were in their late 60s (median 69 years) and
able to do little for themselves (median pal-
liative performance score 50%). Thirty five
per cent (703) were bedbound all or most of
the time, and 38% (755) lived alone.
Thirty one per cent (619) were dis-
charged home, 28% (568) died in Ninewells;
and 28% were transferred to another place
of care (458 to a hospice, 110 to a district or
community hospital or nursing home).
Twelve per cent (245) were discharged back
to the referring team.
Patients discharged home had a better
performance status than those who did not
(figure). The probability of getting home
with a performance status of 60 or more was
better than 1 in two patients (55%; 343/619),
but as performance status fell to 40 or less,
probability was < 1 in 10 patients (9.5%;
67/703).
Current community palliative care serv-
ices are not sufficiently funded to offer a
serious alternative to acute hospital care for
most patients.
Pam Levack consultant in palliative medicine
pamela.levack@tpct.scot.nhs.uk
Helen Dryden Macmillan clinical nurse specialist
Fiona Paterson clinical assistant
Ninewells Hospital Palliative Care Team, Dundee
DD9 1SY
Competing interests: None declared.
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1 Murray SA, Boyd K, Sheikh A, Thomas K, Higginson IJ.
Developing primary palliative care. BMJ 2004;329:1056-7.
(6 November.)
2 Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Pal-
liative performance scale [PPS]: a new tool. J Palliat Care
1996;12:5-11.
Screening may not reduce
suicide in later life
Editor—O’Connell et al are wise to warn
against a reductionist approach to the com-
plex topic of suicide in older people since an
epidemiological perspective makes older
people who commit suicide into objects of
disease processes rather than subjects strug-
gling to control their lives.1 They also
prescribe vigorous screening and aggressive
treatment despite the difficulties in reaching
the highest risk group, reluctance to accept
stigmatising labels, and the limited efficacy
of available interventions.
Much seems to depend on the meaning
of problems for individual people. Proud but
rather rigid people who would rather not live
if unable to do so with their normal vigour
may opt for suicide, especially if depressed
mood alters their judgment about their illness
or disability. Older men living alone whose
lives are changed for the worse by loss may be
the highest risk group, but they may also be
those least likely to engage with services.
We do not advocate therapeutic nihil-
ism, but the limitations must be understood.
Coping strategies built over a lifetime can
collapse under the impact of successive
adverse events, and professionals’ ability to
influence either coping strategies or adverse
events is limited. A perceived failure to pre-
vent suicide can have adverse effects on
social and healthcare workers, so policies for
identifying those at risk need to be realistic.
Better management of disabilities, improved
pain control, and greater financial security
for vulnerable older people, with antidepres-
sant and psychological treatments on offer
to those with depression symptoms, may be
more positive approaches than vigorous
screening.
Steve Iliffe reader in general practice
Department of Primary Care and Population
Sciences, Royal Free and UCL Medical School,
London NW3 2PF
s.iliffe@pcps.ucl.ac.uk
Jill Manthorpe professor of social work
Social Care Workforce Research Unit, King’s
College, London SE1 9NN
Jill.Manthorpe@kcl.ac.uk
Competing interests: None declared.
1 O’Connell H, Chin A, Cunningham C, Lawlor B. Recent
developments: suicide in older people. BMJ 2004;329:
895-9. (16 October.)
Side effects deserve greater
emphasis at end of life
Editor—We agree with many of the points
made by Stevenson et al on managing
comorbidities at the end of life, particularly
the emphasis on assessing the overall
benefits of treatment kept in perspective
through numbers needed to treat or
absolute risk reduction, often much smaller
than the relative risk reductions more
commonly cited.1 2
We believe that side effects deserve
greater emphasis. Pharmacokinetics and
sensitivities to drugs are often more marked
and less predictable in disease, as Stevenson
et al say.With this comes an increased risk of
doing harm. For example, the risk of
oesophageal perforation associated with
bisphosphonate treatment is increased
because of reduced oesophageal motility
and difficulty remaining erect for the requi-
site half hour.
The authors say that current and emerg-
ing evidence can help generate a framework
to improve clinical decision making in
patients at the end of their life. The patient
population discussed is invariably excluded
from the trials investigating many of the
conditions mentioned. For these patients,
the same effects of treatment cannot be
assumed, and decisions must be made
empirically. This is a situation that we cannot
envisage changing.
One recently described approach that
may help guide clinicians involves dividing
patients into four categories according to
the style of care provided—aggressive man-
agement, usual, palliative (emphasis on
symptom control but no secondary preven-
tion), and terminal care. 3
Adam Harper acting consultant geriatrician
adamharper@doctors.org.uk
Jan Ritchie registrar
Jeremy Rowland senior house officer
Vladimir Malykh honorary preregistration house officer
Department of Medicine for Older People,
Southampton General Hospital, Southampton
SO16 6YD
Competing interests: None declared.
1 Stevenson J, Abernethy AP, Miller C, Currow DC. Manag-
ing comorbidities in patients at the end of life. BMJ
2004;329:909-12. (16 October.)
2 Bogaty P, Brophy J. Increasing burden of treatment in the
acute coronary syndromes: is it justified? Lancet
2003;361:1813-6.
3 Vanpee D, Swine C. Scale of levels of care versus DNR
orders. J Med Ethics 2004;30:351-2.
Paediatric cardiac surgical
mortality after Bristol
Details of risk adjustment tools were not
given
Editor—The paper by Aylin et al on paedi-
atric cardiac mortality in England after Bris-
tol provides some interesting and potentially
perturbing results.1 The reduction in paedi-
atric cardiac surgical mortality is encourag-
ing, but the identification of hospitals with
excess mortality is worrying.
Since 2003 all paediatric intensive care
units in England and Wales have contrib-
uted data on all admissions to the paediatric
intensive care audit network (PICANet),
funded by the Department of Health.2 Fami-
lies of patients treated in paediatric intensive
care units in the United Kingdom may be
reassured that in the data thus far reported
no unit has an unexpectedly high mortality.
The method of analysis used by
PICANet may be superficially similar to that
used by Aylin et al, but on closer inspection
it may not. PICANet produces mortality
ratios that are carefully adjusted for the
illness severity of children on admission to
the unit using published risk adjustment
tools.3 This results in clearly different
distributions of mortality ratios by unit when
plotting crude (unadjusted) and adjusted
mortality. Thus, ranking units according to
their mortality will result in a different order
when using crude and adjusted mortality.
This phenomenon has been found else-
where when good quality risk adjustment is
applied.4 5 It is curious therefore that the dis-
tribution of crude mortality seen in Aylin et
al’s supplemental figures is almost equiva-
lent to that of the adjusted odds ratios seen
in the main paper.
Although, with perfect risk adjustment
this can happen, a more likely and troubling
cause could be the lack of valid and
appropriate risk adjustment. Aylin et al do
not describe the method of risk adjustment.
The NHS must identify areas of the service
that are falling behind in performance, but
valid, reliable, and robust scientific tech-
niques must be used to do this. To provide
reassurance and therefore support to their
work, Aylin et al must provide clear details of
the adequacy of the risk adjustment tools
they used in this study.
Gareth Parry reader in health services research
Health Services Research, University of Sheffield,
Sheffield S1 4DA
g.parry@sheffield.ac.uk
Elizabeth S Draper senior research fellow
Department of Epidemiology and Public Health,
University of Leicester, Leicester LE1 6TP
Patricia McKinney reader in paediatric epidemiology
Paediatric Epidemiology Group, University of
Leeds, Leeds LS2 9LN
Competing interests: None declared.
1 Aylin P, Bottle A, Jarman B, Elliot P. Paediatric cardiac sur-
gical mortality in England after Bristol: descriptive analysis
of hospital episode statistics 1991-2002. BMJ
2004;329:825-7. (9 October.)
2 Universities of Leeds, Leicester, and Sheffield. PICANet
annual report. May 2004.
3 Shann F, Pearson G, Slater A, Wilkinson K. Paediatric
index of mortality (PIM): a mortality prediction model for
children in intensive care. Intensive Care Med 1997;
23:201-7.
4 Parry GJ, Gould CR, McCabe CJ, Tarnow-Mordi WO.
Annual league tables of hospital mortality in neonatal
intensive care: longitudinal study. BMJ 1998;316:1931-5.
5 Marshall EC, Spiegelhalter DJ, Sanderson C, McKee M.
Reliability of league tables of in vitro fertilisation clinics:
retrospective analysis of live birth rates. BMJ
1998;316:1701-5.
Paediatric cardiac hospital episode
statistics are unreliable
Editor—The lack of accuracy of the
hospital episode statistics used by Aylin et al
to analyse the paediatric cardiac surgical
mortality in England after Bristol is worry-
ing.1 Indeed, Aylin’s group reported that
hospital episode statistics “manifestly con-
tain errors” and that their available data
sources “have such clear limitations that one
could ask whether any reliable conclusions
can be drawn.”2 We have also shown hospital
episode statistics data to be inaccurate for
this complex specialty.3
Details of the palliative performance scale
are on bmj.com
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This latest study raises more concerns
about hospital episode statistics data, show-
ing that errors are not consistent across the
country.1 A centre with a high proportion of
outcome returns from hospital episode
statistics (Oxford, for example) would almost
inevitably identify more
deaths than one with low
returns, potentially giving a
false impression of relative
surgical performance.
The central cardiac audit
database collects, validates,
and analyses data from all
UK paediatric cardiac units,
centrally tracking mortality
using direct links to the
Office for National Statistics
(where all deaths in England
are registered). It started collecting data in
2000, so it does not have comprehensive
data for comparison with all the epochs
described by Aylin et al, but it has data on
2913 infants who had open heart operations
in England during 2000-2.
Aylin et al report only 2607 infant
operations in epoch 6 (1999-2002), which
implies serious errors in their case ascertain-
ment. They report an overall English
perioperative mortality for infant open
heart operations in epoch 6 of 4%, with 105
deaths identified over the three years. The
central cardiac audit database has identified
185 deaths (7.8% mortality) in the cohort of
2385 open heart infant operations during
2000-2, its validated, centre specific mortal-
ity for all open heart infant operations in
England for 2000-2 ranging between 3.3%
and 10.7%. Two centres had higher mortal-
ity than Oxford, in contrast to Aylin et al’s
report. The 95% confidence intervals for
difference in mortality between Oxford and
all of England were − 4.1% to 8.7%, a large
overlap, which means any difference is
statistically insignificant.
John L Gibbs lead clinician for congenital heart
disease, central cardiac audit database
jgibbs@boltblue.com
Leeds General Infirmary, Leeds LS1 3EX
David Cunningham project manager, central cardiac
audit database
National Clinic Audit Support Programme, NHS
Information Authority, Tavistock House, London
WC1H 9JR
Marc de Leval professor of cardiac surgery
Great Ormond Street Hospital for Children,
London WC1N 3JH
James Monro consultant cardiac surgeon
Southampton General Hospital, Southampton
SO16 6YD
Bruce Keogh professor of cardiac surgery
University College Hospital, London
Competing interests: None declared.
1 Aylin P, Bottle A, Jarman B, Elliot P. Paediatric cardiac sur-
gical mortality in England after Bristol: descriptive analysis
of hospital episode statistics 1991-2002. BMJ 2004;329:
825-7. (9 October.)
2 Aylin P, Alves B, Best N, Cook A, Elliott P, Evans SJ, et al.
Comparison of UK paediatric cardiac surgical perform-
ance by analysis of routinely collected data 1984-1996: was
Bristol an outlier? Lancet 2001;358:181-7.
3 Gibbs JL, Monro JL, Cunningham D, Rickards A. Survival
after surgery or therapeutic catheterisation for congenital
heart disease in children in the United Kingdom: analysis
of the central cardiac audit database for 2000-1. BMJ
2004;328:611-5.
Authors’ reply
Editor—Parry et al call for clarity of our
methods for risk adjustment. We adjusted
by type of operation, by incorporating the
11 open procedure groups as factors
into our regression model. The use of
procedure groups for risk
adjustment is in line with
another published method.1
In contrast, recently pub-
lished centre comparisons
based on the central cardiac
audit database were not risk
adjusted.2
Gibbs et al and Morris
and Archer on bmj.com
remain concerned by the
lack of accuracy of hospital
episode statistics.3 Work
commissioned by the Bristol inquiry
showed reasonable agreement between
these and the UK cardiac surgical register.
Hospital episode statistics also recorded
99% of 30 day postoperative deaths in
hospital for the procedures of interest.4
Morris and Archer confirm that the
Oxford centre was approached by the
Department of Health in 2001 on the basis
of both hospital episode statistics data and
cardiac surgical register returns since 1995,
in which it was thought that it was an outlier
with respect to transposition of the great
arteries in infants.3 Oxford was
also aware of a possible downturn in its
results and consequently ceased such
surgery in 2000 (J Morris, personal
communication).
Differences between analyses of the cen-
tral cardiac audit database and our own are
not necessarily inconsistent.
Firstly, we look only at mortality in
hospital, and results published from the
database include all perioperative deaths.
Secondly, hospital episode statistics lack
an indicator to specify whether an operation
is open, and so this must be inferred from
the operation code. We exclude any opera-
tions that could be either open or closed,
which could account for the alleged
shortfall. However, we also examined mor-
tality in a group of 11 well defined open
procedures, which gave similar results
between centres.
Lastly, Gibbs et al provide central
cardiac audit database results for a different
time. Oxford has confirmed to us that it
stopped transposition of the great arteries
because of several deaths in late 1999
(hence included in our analysis but not
included in figures from the central cardiac
audit database) and early 2000 (J Morris,
personal communication).
Hospital episode statistics is the only
available database spanning our period
of analysis from 1991 to 2002. It is
coded independently of clinicians and is
available for public scrutiny. Further col-
laborative work to identify and correct
inconsistencies between hospital episode
statistics and clinical datasets might be a
useful consequence of our work and could
enhance the credibility of both sources of
data.
Paul Aylin clinical senior lecturer
p.aylin@imperial.ac.uk
Brian Jarman emeritus professor
Paul Elliott professor of epidemiology and public
health, faculty of medicine
Dr Foster Unit at Imperial College London,
Department of Epidemiology and Public Health,
St Mary’s Campus, Imperial College, London
W2 1PG
Competing interests: The work was funded by Dr
Foster Limited. BJ served on the panel for the
Bristol Royal Infirmary inquiry. PA was an expert
witness for the inquiry.
1 Jenkins K, Gauvreau K, Newburger J, Spray T, Moller J, Iez-
zoni L. Consensus-based method for risk adjustment for
surgery for congenital heart disease. J Thorac Cardiovasc
Surg 2002;123:110-8.
2 Gibbs JL, Monro JL, Cunningham D, Rickards A. Survival
after surgery or therapeutic catheterisation for congenital
heart disease in children in the United Kingdom: analysis
of the central cardiac audit database for 2000-1. BMJ
2004;328:611-5.
3 Morris J, Archer N. Paediatric cardiac surgical mortality.
Electronic response to: Paediatric cardiac surgical mortal-
ity in England after Bristol. bmj.com 2004. http://
bmj.bmjjournals.com/cgi/eletters/329/7470/
825[77793 (accessed 16 Dec 2004).
4 Aylin P, Alves B, Best N, Cook A, Elliott P, Evans SJW, et al.
Comparison of UK paediatric cardiac surgical perform-
ance by analysis of routinely collected data 1984-96: was
Bristol an outlier? Lancet 2001;358:181-7.
Patients’ interests: paramount
in randomised trials
Editor—Patients and the public recognise
the need for large randomised trials.
Trialists must also recognise the responsi-
bilities they owe to their study participants.
There has been some debate on whether
these responsibilities are always fully
discharged.
The early stopping of the MA17 trial,
with data released to the media before the
trial participants or health professionals had
been given time to assess the implications,
led to speculation in the medical press about
how far patients’ interests were being
considered.1 Similarly, recent articles have
alleged that several pharmaceutical
companies may have withheld product
safety data, ranging from harmful effects of
paroxetine in adolescents, to cardiovascular
events associated with rofecoxib, with
consequent speculation about the possibil-
ity of similar adverse effects from other
COX-2 inhibitors.2 3
Sir Tom McKillop, the chief executive
officer of AstraZeneca, said: “If we put
consumer protection as the only thing the
regulator needs to worry about, that will be a
huge block to progress and innovation.”4
This may dissuade potential trial partici-
pants from entering studies because of a
perceived (or real) lack of concern for their
welfare and rights.
Research must be based on collaborative
partnerships between patients and profes-
sionals in industry and academia—a key
objective of the National Cancer Research
Institute. This approach will help ensure the
proper conduct of clinical studies, reduce
treatment uncertainties, help patients to
understand potential risks and benefits, and
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improve the public perception of clinical
research.
Tony Stevens consumer liaison lead
t.stevens@ncrn.org.uk
Roger Wilson chair, National Cancer Research
Institute Consumer Liaison Group
National Cancer Research Network, Cookridge
Hospital, Leeds LS16 6QB
Competing interests: None declared.
1 Baum M. Current status of aromatase inhibitors in the
management of breast cancer and critique of the NCIC
MA-17 trial. Cancer Control 2004;11:217-21.
2 Singh D. Merck withdraws arthritis drug worldwide. BMJ
2004;329:816-2. (9 October.)
3 Horton R. Vioxx: an unequal partnership between safety
and efficacy. Lancet 2004;364:1287-8.
4 Man of science with a passionate belief in innovation. Inde-
pendent 2004 October 9:59.
Placebos in medicine
Placebo use is well known, placebo effect
is not
Editor—In their paper on the use of
placebos in clinical practice, Nitzan and
Lichtenberg say that they were unable to
find more than one other study on the use of
placebos in a clinical context.1 2 Eight similar
studies are indexed in PubMed (see bmj.com).
In the accompanying editorial, Spiegel
points out that the Cochrane review on the
placebo effect probably underestimated the
placebo effects of treatments.3 4 Spiegel gave
some methodological explanations for this
underestimation but did not mention a
much more important reason.
A problem with the Cochrane review, as
mentioned in three letters by Lilford and
Braunholtz, Kuppers, and Shrier,5 is that the
included studies were done in a setting
completely different from the situation in
clinical practice. The included studies are three
armed studies, in which patients are randomly
allocated to a supposedly active treatment, to a
placebo, or to no treatment. The placebo effect
is then defined as the difference in effect in the
patients receiving placebo compared with
those receiving no treatment.
Obviously, neither the patient nor the
doctor in such a trial will have any substantial
belief in the (placebo) treatment or consider
it particularly meaningful. This situation is
completely different from clinical practice,
where the patient and the doctor believe in
the therapeutic powers of a treatment that
they probably consider meaningful. The
difference between randomised trials and
clinical practice is always a problem, but
much more so in the study of placebos and
related phenomena. This is one of the main
reasons why the Cochrane review does not
exclude the existence of strong placebo
effects in some situations of clinical practice.
Toke S Barfod clinical researcher
Department of Infectious Diseases, Rigshospitalet,
2100 Copenhagen, Denmark
Toke.barfod@dadlnet.dk
Competing interests: None declared.
1 Nitzan U, Lichtenberg P. Questionnaire survey on use of
placebo. BMJ 2004;329:944-6. (23 October.)
2 Goodwin JS, Goodwin JM, Vogel AV. Knowledge and use
of placebos by house officers and nurses. Ann Intern Med
1979;91:106-10.
3 Spiegel D. Placebos in medicine. BMJ 2004;329:927-8.
(23 October.)
4 Hrobjartsson A, Gotzsche PC. Is the placebo powerless?
An analysis of clinical trials comparing placebo with no
treatment. N Engl J Med 2001;344:1594-602.
5 Correspondence. Is the placebo powerless? N Engl J Med
2001;345:1276-9.
Medical paradoxes need disentangling
Editor—As Spiegel’s editorial highlights,1
paradoxes around the placebo effect can be
overcome by distinguishing between a
dummy pill and the effects of thoughts, feel-
ings, and human relationships.2
Placebos may seem like a less toxic solu-
tion than pharmacological treatments for
functional or chronic conditions but this
carries side effects—disrupt trust, and out-
come is disturbed. Doctors in Israel give pla-
cebo treatments without informing their
patients, at trial closure investigators often
don’t tell people if they got placebo,3 and
patients often turn to complementary medi-
cine without informing their doctors.
The issue should not be about prescrib-
ing placebos but rather about the need to
increase our general knowledge around
healing mechanisms,4 to harness directly
what placebo harnesses indirectly, in an
ethical and practical manner, encouraging a
sense of trust and partnership between the
public and healthcare specialists.
Placebo effect research presents evi-
dence of the extent to which individuals
possess natural self healing capabilities that
can be nurtured in a healthcare interaction.5
A medical system that does not place central
value on doctors taking time to establishing
safe, trusting and collaborative relationships,
is not “evidence based” and ignores the
obvious impact on outcome from the quality
of human caring, becoming less cost
effective in the long run.
It is time we stop considering percep-
tions, feelings, and human interactions in
health care as variables that need to be con-
trolled in the pursuit of medical science but
include and study these as critically meaning-
ful mediators and moderators of therapeutic
outcomes in clinical trials, and daily care.
Zelda Di Blasi postdoctoral fellow
University of California San Francisco, San
Francisco, CA 94143, USA
DiBlasi@ocim.ucsf.edu
David Reilly consultant physician
Centre for Integrative Care, Glasgow Homeopathic
Hospital, Glasgow
Competing interests: None declared.
1 Spiegel D. Placebos in medicine. BMJ 2004;329:927-8.
(23 October.)
2 Di Blasi Z, Kleijnen J. Context effects. Powerful therapies or
methodological bias? Eval Health Prof 2003;26:166-79.
3 Di Blasi Z, Kaptchuk TJ, Weinman J, Kleijnen J. Informing
participants of allocation to placebo at trial closure: postal
survey. BMJ 2002;325:1329.
4 Reilly D. Enhancing human healing. BMJ 2001;322:120-1.
5 Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J.
Influence of context effects on health outcomes: a system-
atic review. Lancet 2001;357:757-62.
Is placebo analgesia always in the mind?
Editor—Spiegel discussed placebos in
medicine.1 A study published in the 1979
edition of Advances in Pain Research and
Therapy offered a tantalising glimpse of a
possible mechanism for placebo analgesia.2
A hundred or so patients who had their
wisdom teeth extracted were assigned (ran-
dom double blind) to a fixed dose of an
opiate or the same volume of saline for post-
operative analgesia. The difference in the
proportion of patients in the opiate versus
the saline group who expressed satisfactory
pain relief did not reach significance. Placebo
analgesia worked in a case of organic pain,
postoperative pain.
The researchers then broke the code
after collecting analgesia data and then ran-
domised (again double blind) the saline
responders to saline or a dose of naloxone.
All the saline responders who received
naloxone complained of their pain again.
This indicates that endogenous analgesic
systems of encephalins or endorphins might
be important.
So is placebo analgesia all in the mind?
Or does the mind work through known
neuropharmacological pathways?
Peter K K Au-Yeung specialist anaesthetist
Department of Anaesthesia, Yan Chai Hospital,
Tsuen Wan, New Territories, Hong Kong SAR, China
lovpetay@netvigator.com
Competing interests: None declared.
1 Spiegel D. Placebos in medicine. BMJ 2004;329:927-8. (23
October.)
2 Levine JD, Gordon NC, Fields HL. The role of endorphins
in placebo analgesia. In: Bonica JJ, ed. Advances in pain
research and therapy. Vol.3. New York: Raven Press, 1979:
547-51.
Pain that is relieved by placebo is not
therefore unreal
Editor—In his editorial on placebos in
medicine Spiegel rightly says that it is not
because pain is relieved by placebo that it is
not real.1
I would go one step further. As Professor
Raymond Villey, one of my teachers in
Caen, told me almost 30 years ago: “Beware
of the pain that cedes to placebo: it’s most
certainly organic.”
I have seen that proved again and again.
I have no explanation other than the one
given for the soldiers at Anzio: the patient
with “real” pain wants it to go away so much
that any straw will be clutched at to relieve
the pain, including placebo. On the other
hand, the patient with “psychological” pain
gains from the pain in some manner. There
will be much less incentive to see the pain
relieved, and placebo may be as ineffective
as the other pain treatment.
As for the dose-response to placebo, in
clinical trials the adverse reactions to place-
bos of high dose non-steroidal anti-
inflammatory drugs are much more com-
mon than those to placebos of low dose
non-steroidal anti-inflammatory drugs.2
Explanations to the fore, please.
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Details of eight studies of placebos are on
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